# EDGAR Filing Document

**Accession Number:** 0001096752
**File Stem:** 0001628280-26-006288
**Filing Date:** 2026-2
**Character Count:** 135640
**Document Hash:** 64c498155ad534cfb587b711f3649c98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-006288.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0001628280-26-006288

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 91

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EDGEWELL PERSONAL CARE Co
- **CENTRAL INDEX KEY:** 0001096752
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 431863181
- **STATE OF INCORPORATION:** MO
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15401
- **FILM NUMBER:** 26610758

**BUSINESS ADDRESS:**
- **STREET 1:** 6 RESEARCH DRIVE
- **CITY:** SHELTON
- **STATE:** CT
- **ZIP:** 06484
- **BUSINESS PHONE:** 203-944-5500

**MAIL ADDRESS:**
- **STREET 1:** 6 RESEARCH DRIVE
- **CITY:** SHELTON
- **STATE:** CT
- **ZIP:** 06484

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ENERGIZER HOLDINGS INC
- **DATE OF NAME CHANGE:** 19991013

?xml version='1.0' encoding='ASCII'? epc-20251231

 **UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________

**FORM 10-Q**

_______________________________

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _______________ to _______________**

**Commission File Number: 001-15401**

____________________________________________________________________________________________________________

![edgewelllogo123118a06.jpg](epc-20251231_g1.jpg)

**EDGEWELL PERSONAL CARE COMPANY**

**(Exact name of registrant as specified in its charter)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Missouri** | **Missouri** | **Missouri** | **43-1863181** | **43-1863181** |
| **(State or other jurisdiction of incorporation or organization)** | **(State or other jurisdiction of incorporation or organization)** | **(State or other jurisdiction of incorporation or organization)** | **(I. R. S. Employer Identification No.)** | **(I. R. S. Employer Identification No.)** |
| **6 Research Drive** | **6 Research Drive** | **6 Research Drive** | **(203)** | **944-5500** |
| **Shelton,** | **CT** | **06484** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |
| **(Address of principal executive offices) (zip code)** | **(Address of principal executive offices) (zip code)** | **(Address of principal executive offices) (zip code)** |  |  |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | EPC | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

Common shares, $0.01 par value - 46,716,605 shares as of January 31, 2026.

------

***Forward-Looking Statements***

This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of Edgewell Personal Care Company or any of our businesses (the "Company"). These forward-looking statements include, but are not limited to, statements concerning our expectations regarding our future results of operations and financial condition; capital expenditures; our restructuring and productivity initiatives; our strategy; impacts from the divestiture of our Feminine Care segment; the effect of macroeconomic factors, including tariffs and inflationary pressures; anticipated trends, seasonality, and challenges in our business and in the markets in which we operate. Additional forward-looking statements may appear throughout this report, including, without limitation, the following sections: Management's Discussion and Analysis, Risk Factors, and the Notes to the Condensed Consolidated Financial Statements. Forward-looking statements generally can be identified by the use of words or phrases such as "believe," "expect," "expectation," "anticipate," "may," "could," "intend," "estimate," "plan," "target," "predict," "likely," "will," "should," "forecast," "outlook," "strategy," or other similar words or phrases. These statements are not based on historical facts, but instead reflect our expectations, estimates or projections concerning future results or events, including, without limitation, the future earnings and performance of the Company or any of our businesses. Many factors outside our control could affect the realization of these estimates. These statements are not guarantees of performance and are inherently subject to known and unknown risks, uncertainties and assumptions that are difficult to predict and could cause our actual results to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this report are only made as of the date of this report, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. You should not place undue reliance on these statements. Factors that could cause fluctuations in our actual results include, but are not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to compete in products and prices, as well as costs, in an intensely competitive industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the loss of any of our principal customers or changes in the policies of our principal customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our inability to design and execute a successful omnichannel strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract, retain and develop key personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in the price and supply of raw materials and costs of labor, warehousing and transportation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of seasonal volatility on our sales, financial performance, working capital requirements and cash flow;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to successfully manage evolving global financial risks, including tariffs, foreign currency fluctuations, currency exchange or pricing controls and localized volatility;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impacts from any loss of our principal customers or changes in the policies or strategies of our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our level of indebtedness and the various covenants related thereto, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our failure to maintain our brands' reputation and successfully respond to changing consumer habits; and perceptions of certain ingredients, negative perceptions of packaging, lack of recyclability or other environmental attributes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our access to capital markets and borrowing capacity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impairment of our goodwill and other intangible assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to successfully manage the financial, legal, reputational and operational risks associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with our international operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to effectively integrate acquired companies and successfully manage divestiture activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully implement our cost savings initiatives, including rationalization or restructuring efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to rely on and maintain key Company and third-party information and operational technology systems, networks and services and maintain the security and functionality of such systems, networks and services and the data contained therein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to successfully achieve, maintain or adjust our environmental or sustainability goals and priorities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to successfully manage current and expanding regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, manufacturing processes, intellectual property, labor and employment, antitrust, privacy, cybersecurity and data protection, artificial intelligence, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending matters within current estimates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to adequately protect our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• product quality and safety issues, including recalls and product liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• losses or increased funding and expenses related to our pension plans; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the other important factors described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2025 ("2025 Annual Report") under Part I. Item 1A. "Risk Factors," and in our other filings with the Securities and Exchange Commission ("SEC").

In addition, other risks and uncertainties not presently known to us or that we presently consider immaterial could significantly affect the forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

------

**EDGEWELL PERSONAL CARE COMPANY**

**INDEX TO FORM 10-Q**

---

| | | |
|:---|:---|:---|
| **PART I.** | **FINANCIAL INFORMATION** | |
| Item 1. | Financial Statements |  |
|  | Condensed Consolidated Statements of Earnings and Comprehensive Income for the three months ended December 31, 2025 and 2024 | <u>[3](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_16)</u> |
|  | Condensed Consolidated Balance Sheets as of December 31, 2025 and September 30, 2025 | <u>[4](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_19)</u> |
|  | Condensed Consolidated Statements of Cash Flows for the three months ended December 31, 2025 and 2024 | <u>[5](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_22)</u> |
|  | Condensed Consolidated Statements of Changes in Shareholders' Equity for the three months ended December 31, 2025 and 2024 | <u>[6](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_25)</u> |
|  | Notes to Condensed Consolidated Financial Statements | <u>[7](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_28)</u> |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>[26](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_79)</u> |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | <u>[35](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_100)</u> |
| Item 4. | Controls and Procedures | <u>[35](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_103)</u> |
| **PART II.** | **OTHER INFORMATION** |  |
| Item 1. | Legal Proceedings | <u>[36](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_1201)</u> |
| Item 1A. | Risk Factors | <u>[36](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_109)</u> |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | <u>[36](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_112)</u> |
| Item 5. | Other Information | <u>[36](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_115)</u> |
| Item 6. | Exhibits | <u>[37](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_118)</u> |
| **SIGNATURE** |  | <u>[38](#i469f6a71cc4c40cc8d1bdb5e87c4fcfc_121)</u> |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

 **EDGEWELL PERSONAL CARE COMPANY**

**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME**

(unaudited, in millions, except per share data)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| &nbsp;&nbsp;Net sales | $422.8 | $415.1 |
| &nbsp;&nbsp;Cost of products sold | 261.8 | 242.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Gross profit** | 161.0 | 172.5 |
| &nbsp;&nbsp;Selling, general and administrative expense | 102.4 | 99.6 |
| &nbsp;&nbsp;Advertising and sales promotion expense | 45.6 | 46.1 |
| &nbsp;&nbsp;Research and development expense | 13.8 | 13.4 |
| &nbsp;&nbsp;Restructuring charges | 18.1 | 4.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating (loss) income** | (18.9) | 9.3 |
| &nbsp;&nbsp;Interest expense associated with debt | 19.3 | 18.8 |
| &nbsp;&nbsp;Other (income) expense, net | (1.3) | 3.2 |
| &nbsp;&nbsp;**Loss from continuing operations before income taxes** | (36.9) | (12.7) |
| &nbsp;&nbsp;Income tax benefit on continuing operations | (7.7) | (2.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net loss from continuing operations** | (29.2) | (10.1) |
| &nbsp;&nbsp;(Loss) earnings from discontinued operations, net of tax | (36.5) | 8.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | $(65.7) | $(2.1) |
| &nbsp;&nbsp;**Basic earnings (loss) per share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $(0.63) | $(0.21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | (0.78) | 0.17 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Basic loss per share** | $(1.41) | $(0.04) |
| &nbsp;&nbsp;**Diluted earnings (loss) per share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $(0.63) | $(0.21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | (0.78) | 0.17 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Diluted loss per share** | $(1.41) | $(0.04) |
| &nbsp;&nbsp;**Weighted-average shares outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 46.6 | 48.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 46.6 | 48.7 |
| &nbsp;&nbsp;**Statements of Comprehensive Income:** |  |  |
| &nbsp;&nbsp;Net loss | $(65.7) | $(2.1) |
| &nbsp;&nbsp;*Other comprehensive income (loss), net of tax* |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustments | 3.2 | (48.3) |
| &nbsp;&nbsp;Pension and postretirement activity, net of tax provision of $0.2 and $0.4 | 0.6 | 0.4 |
| &nbsp;&nbsp;Deferred gain on hedging activity, net of tax provision of $0.7 and $2.3 | 1.5 | 5.0 |
| &nbsp;&nbsp;**Total other comprehensive income (loss), net of tax** | 5.3 | (42.9) |
| &nbsp;&nbsp;**Total comprehensive loss** | $(60.4) | $(45.0) |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

**EDGEWELL PERSONAL CARE COMPANY**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

(unaudited, in millions, except share data)

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| **Assets** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $223.3 | $225.7 |
| &nbsp;&nbsp;Trade receivables, less allowance for doubtful accounts of $4.5 and $4.8 | 154.0 | 137.8 |
| &nbsp;&nbsp;&nbsp;Inventories | 461.2 | 433.8 |
| &nbsp;&nbsp;&nbsp;Other current assets | 161.6 | 138.6 |
| &nbsp;&nbsp;&nbsp;Current assets held for sale | 57.0 | 59.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1057.1 | 995.5 |
| Property, plant and equipment, net | 292.5 | 295.0 |
| Goodwill | 1137.4 | 1137.1 |
| Other intangible assets, net | 821.8 | 828.2 |
| Other assets | 179.1 | 178.7 |
| Non-current assets held for sale | 280.0 | 321.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $3767.9 | $3756.3 |
| **Liabilities and Shareholders' Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable | $32.5 | $29.5 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 213.1 | 219.7 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 247.9 | 311.1 |
| &nbsp;&nbsp;&nbsp;Current liabilities held for sale | 4.0 | 5.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 497.5 | 565.5 |
| Long-term debt | 1520.8 | 1383.3 |
| Deferred income tax liabilities | 118.3 | 118.8 |
| Other liabilities | 145.1 | 135.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2281.7 | 2203.2 |
| Shareholders' equity |  |  |
| Preferred shares, $0.01 par value, 10,000,000 authorized; none issued or outstanding |  |  |
| Common shares, $0.01 par value, 300,000,000 authorized; 65,251,989 issued; 46,716,605 and 46,464,244 outstanding | 0.7 | 0.7 |
| Additional paid-in capital | 1560.6 | 1578.8 |
| Retained earnings | 1014.0 | 1086.7 |
| Common shares in treasury at cost, 18,535,384 and 18,787,745 | (984.6) | (1003.3) |
| Accumulated other comprehensive loss | (104.5) | (109.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 1486.2 | 1553.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $3767.9 | $3756.3 |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

**EDGEWELL PERSONAL CARE COMPANY**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(unaudited, in millions)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| **Cash Flow from Operating Activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(65.7) | $(2.1) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 21.3 | 21.7 |
| &nbsp;&nbsp;&nbsp;Share-based compensation expense | 3.4 | 6.1 |
| &nbsp;&nbsp;&nbsp;Loss on sale of assets |  | 1.4 |
| &nbsp;&nbsp;&nbsp;Impairment charges | 37.4 |  |
| &nbsp;&nbsp;&nbsp;Loss on assets held for sale | 3.8 |  |
| &nbsp;&nbsp;&nbsp;Deferred compensation payments | (0.2) | (0.2) |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | (0.9) | 0.2 |
| &nbsp;&nbsp;&nbsp;Other, net | 12.5 | 2.3 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities | (137.5) | (145.0) |
| Net cash used for operating activities | (125.9) | (115.6) |
| **Cash Flow from Investing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (11.6) | (16.8) |
| &nbsp;&nbsp;&nbsp;Collection of deferred purchase price on accounts receivable sold | 1.7 | 1.1 |
| Net cash used for investing activities | (9.9) | (15.7) |
| **Cash Flow from Financing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;Cash proceeds from debt with original maturities greater than 90 days | 292.0 | 369.0 |
| &nbsp;&nbsp;&nbsp;Cash payments on debt with original maturities greater than 90 days | (155.0) | (204.0) |
| &nbsp;&nbsp;&nbsp;Proceeds from debt with original maturities of 90 days or less | 2.4 | 3.7 |
| &nbsp;&nbsp;&nbsp;Repurchase of shares |  | (30.3) |
| &nbsp;&nbsp;&nbsp;Dividends to common shareholders | (7.4) | (7.9) |
| &nbsp;&nbsp;&nbsp;Net financing inflow (outflow) from the Accounts Receivable Facility | 4.3 | (13.3) |
| &nbsp;&nbsp;&nbsp;Employee shares withheld for taxes | (2.8) | (7.3) |
| &nbsp;&nbsp;&nbsp;Other, net | (0.1) |  |
| Net cash provided by financing activities | 133.4 | 109.9 |
| Effect of exchange rate changes on cash |  | (12.2) |
| Net decrease in cash and cash equivalents | (2.4) | (33.6) |
| Cash and cash equivalents, beginning of period | 225.7 | 209.1 |
| Cash and cash equivalents, end of period | $223.3 | $175.5 |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

**EDGEWELL PERSONAL CARE COMPANY**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**

(unaudited, in millions)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Shares** | **Common Shares** | **Treasury Shares** | **Treasury Shares** | | | | |
| | **Number** | **Par Value** | **Number** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Total Shareholders' Equity** |
| **Balance as of September 30, 2025** | 65.2 | $0.7 | (18.8) | $(1003.3) | $1578.8 | $1086.7 | $(109.8) | $1553.1 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  |  | (65.7) |  | (65.7) |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments |  |  |  |  |  |  | 3.2 | 3.2 |
| &nbsp;&nbsp;&nbsp;Pension and postretirement activity |  |  |  |  |  |  | 0.6 | 0.6 |
| &nbsp;&nbsp;&nbsp;Deferred gain on hedging activity |  |  |  |  |  |  | 1.5 | 1.5 |
| &nbsp;&nbsp;&nbsp;Dividends declared |  |  |  |  |  | (7.0) |  | (7.0) |
| &nbsp;&nbsp;&nbsp;Repurchase of shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Activity under share plans |  |  | 0.3 | 18.7 | (18.2) |  |  | 0.5 |
| **Balance as of December 31, 2025** | 65.2 | $0.7 | (18.5) | $(984.6) | $1560.6 | $1014.0 | $(104.5) | $1486.2 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Shares** | **Common Shares** | **Treasury Shares** | **Treasury Shares** | | | | |
| | **Number** | **Par Value** | **Number** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Total Shareholders' Equity** |
| **Balance as of September 30, 2024** | 65.2 | $0.7 | (16.3) | $(937.9) | $1586.0 | $1090.1 | $(154.8) | $1584.1 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  |  | (2.1) |  | (2.1) |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments |  |  |  |  |  |  | (48.3) | (48.3) |
| &nbsp;&nbsp;&nbsp;Pension and postretirement activity |  |  |  |  |  |  | 0.4 | 0.4 |
| &nbsp;&nbsp;&nbsp;Deferred gain on hedging activity |  |  |  |  |  |  | 5.0 | 5.0 |
| &nbsp;&nbsp;&nbsp;Dividends declared |  |  |  |  |  | (7.1) |  | (7.1) |
| &nbsp;&nbsp;&nbsp;Repurchase of shares |  |  | (0.8) | (30.1) |  |  |  | (30.1) |
| &nbsp;&nbsp;&nbsp;Activity under share plans |  |  | 0.3 | 23.3 | (24.2) |  |  | (0.9) |
| **Balance as of December 31, 2024** | 65.2 | $0.7 | (16.8) | $(944.7) | $1561.8 | $1080.9 | $(197.7) | $1501.0 |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

**EDGEWELL PERSONAL CARE COMPANY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited, in millions, except per share data)

**Note 1 - Background and Basis of Presentation**

***Background***

Edgewell Personal Care Company and its subsidiaries (collectively, "Edgewell" or the "Company") is one of the world's largest manufacturers and marketers of personal care products in the wet shave and sun and skin care categories. With operations in approximately 20 countries, the Company's products are widely available in more than 50 countries.

The Company conducts its business in the following two segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Wet Shave* consists of products sold under the Schick®, Wilkinson Sword<sup>TM</sup>, Edge, Skintimate®, Billie®, Shave Guard and our custom brands group (formerly sold under our Shave Guard and Personna® brands), as well as non-branded products. The Company's wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Sun and Skin Care* consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men's and women's grooming products, Billie women's grooming products and Wet Ones® products.

See Feminine Care Divestiture in the Basis of Presentation section below for information regarding discontinued operations.

***Basis of Presentation***

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") under the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). The preparation of the unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair statement have been included in the interim results reported. The fiscal year-end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited annual consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on November 18, 2025.

<u>Feminine Care Divestiture</u>

On November 12, 2025, we entered into an agreement to sell our Feminine Care segment to Essity, a leading global health and hygiene company based in Sweden for $340.0. In accordance with applicable accounting guidance, the results of the Feminine Care segment are presented as discontinued operations in the Condensed Consolidated Statements of Earnings and Comprehensive Income and, as such, have been excluded from both continuing operations and segment results for all periods presented. Further, the Company reclassified the assets and liabilities of the Feminine Care disposal group as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets as of December 31, 2025 and September 30, 2025. The Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis with both continuing operations and discontinued operations. All amounts, percentages and disclosures for all periods presented reflect only the continuing operations of Edgewell unless otherwise noted. See Note 2 for additional information.

------

***Recently Issued Accounting Pronouncements***

In September 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *No. ASU No. 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software*. This ASU modernizes the capitalization criteria for internal-use software by eliminating references to project stages and clarifying the threshold applied to begin capitalizing costs. This guidance is effective for the Company for fiscal years beginning after December 15, 2027. The Company is currently assessing the impact of this new guidance.

In November 2024, the FASB issued ASU *No. 2024-03 Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40).* Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. ASU 2024-03 provides guidance to expand disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, on a retrospective or prospective basis, with early adoption permitted. We are currently evaluating this ASU to determine its impact on our consolidated financial statements and disclosures.

In December 2023, the FASB issued *ASU No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures* to update income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively and early adoption is permitted. We are currently assessing the impact of the requirements on our consolidated financial statements and disclosures.

No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial Statements.

***Recently Adopted Accounting Pronouncements***

In November 2023, the FASB issued ASU *No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* to expand reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in the ASU require that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to an entity's chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. Annual disclosures are required for fiscal years beginning after December 15, 2023. Interim disclosures are required for periods within fiscal years beginning after December 15, 2024. Retrospective application is required for all prior periods presented and early adoption is permitted. The Company adopted this ASU as of the fourth quarter of fiscal year 2025. The adoption of this ASU did not have a material effect on the consolidated financial statements. Refer to Note 17 for additional information regarding the Company's segment reporting.

------

**Note 2 - Discontinued Operations**

The divestiture of the Feminine Care segment is a key step to transform Edgewell into a more focused, agile and consumer-driven personal care company. On February 2, 2026, we closed the sale of our Feminine Care segment to Essity and received proceeds of approximately $340.0 on a cash-free and debt-free basis. In the first quarter of fiscal 2026, the assets and liabilities of the segment were classified as held for sale and the segment's results are presented as discontinued operations. This change was applied on a retrospective basis. As of the date we determined the Feminine Care segment to be held for sale, we tested the assets within the disposal group, including goodwill, for impairment and recorded a goodwill impairment loss of $37.4. Fair value of the reporting unit was determined under a market approach and based on the offer received to purchase the disposal group, a Level 3 fair value input.

The following table presents the financial results of Feminine Care included in (Loss) earnings from discontinued operations, net of tax for the three months ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Net sales | $64.0 | $63.3 |
| Cost of products sold | 48.0 | 44.2 |
| **Gross profit** | 16.0 | 19.1 |
| Selling, general and administrative expense | 12.5 | 3.3 |
| Advertising and sales promotion expense | 2.0 | 4.2 |
| Research and development expense | 0.6 | 0.5 |
| Restructuring charges | **0.2** | **0.1** |
| Impairment charges | 37.4 |  |
| **Operating income** | (36.7) | 11.0 |
| Loss on assets held for sale | 3.8 |  |
| **(Loss) earnings from discontinued operations before income taxes** | (40.5) | 11.0 |
| Income tax (benefit) expense on discontinued operations | (4.0) | 3.0 |
| **(Loss) earnings from discontinued operations, net of tax** | $(36.5) | $8.0 |

---

The following table reconciles the gross proceeds with the loss on assets held for sale included in (Loss) earnings from discontinued operations, net of tax:

---

| | |
|:---|:---|
| | **Three Months Ended<br>December 31, 2025** |
| Gross proceeds | $340.0 |
| Less direct costs to sell | 7.0 |
| Less carrying amount | 336.8 |
| Loss on assets held for sale | $3.8 |

---

In the second quarter of 2026, upon deconsolidation of the net assets of the disposal group because of the closing of the transaction, we expect to finalize the calculation of the loss on assets held for sale and an additional loss could occur.

------

The following table presents the carrying amounts of assets and liabilities that are classified as held for sale on the condensed consolidated balance sheet as of December 31, 2025 and September 30, 2025:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **September 30, 2025** |
| Inventories | $48.1 | $50.9 |
| Other current assets | 8.9 | 8.7 |
| **Current assets held for sale** | 57.0 | 59.6 |
| Property, plant and equipment, net | 73.9 | 74.3 |
| Goodwill | 117.0 | 154.0 |
| Other intangible assets, net | 92.7 | 93.1 |
| Other assets | 0.2 | 0.4 |
| Allowance for loss on classification as held for sale | (3.8) |  |
| **Non-current assets held for sale** | 280.0 | 321.8 |
| **Total assets held for sale** | 337.0 | 381.4 |
| Other current liabilities | 4.0 | 5.2 |
| **Current liabilities held for sale** | 4.0 | 5.2 |
| **Total liabilities held for sale** | $4.0 | $5.2 |

---

The following table presents significant cash flow items from discontinued operations for the three months ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Capital expenditures | $0.4 | $1.4 |
| Depreciation and amortization | 1.3 | 3.6 |

---

The goodwill impairment charge of $37.4 and loss on assets held for sale of $3.8 are the material non-cash amounts included in the condensed consolidated statements of cash flows which is included in operating activities for the three months ended December 31, 2025.

In connection with the divestiture, Edgewell entered into a Transition Services Agreement ("TSA") with Essity. Pursuant to the TSA, Edgewell agreed to provide certain services to Essity, on an interim, transitional basis from and after closing for an initial duration of twelve months following the divestiture. The TSA covers various services such as operations and supply chain, IT, commercial, sales and finance, controllership and global business support activities. The remuneration of such services is intended to allow the company to recover a significant portion of its costs and expenses of providing such services.

The costs related to services provided by Edgewell under the TSA will be recorded in continuing operations within the condensed consolidated statement of earnings and comprehensive income beginning in the second quarter of fiscal 2026 following the closing of the transaction. Pass-through costs related to the cost of providing certain services will be recorded in continuing operations as a direct offset within costs of products sold or selling, general and administrative expense and other cost reimbursements will be recorded in other income (expense), net.

------

**Note 3 - Restructuring Charges**

***Operating Model Redesign***

In fiscal 2026, the Company continues to take actions to strengthen its operating model, simplify the organization's ways of working and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, the Company expects to incur restructuring and related charges of approximately $7 in fiscal 2026. The Company has incurred restructuring and related charges as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Severance and related costs | $0.3 | $0.5 |
| Asset write-off and accelerated depreciation |  | 1.0 |
| Other exit costs <sup>(2)</sup> | 1.9 | 0.8 |
| Total restructuring and related charges <sup>(1)(3)</sup> | $2.2 | $2.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Restructuring and related charges of $0.5 and nil are included within Selling, general and administrative expense ("SG&A") for the three months ended December 31, 2025 ad 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes contract related and personnel costs and certain other exit and disposal activities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Restructuring and Related Charges of $0.2 and $0.1 have been included in discontinued operations for three months ended December 31, 2025 and 2024 , respectively. See Note 2, "Discontinued Operations" for additional information.

***Consolidation of Mexico Facilities***

In fiscal 2024, the Company announced certain operational and organizational steps designed to streamline the Company's operations and supply chain by consolidating its current Mexico operations in Obregon and Mexico City into a single facility in Aguascalientes, Mexico. As a result of these actions, the Company is anticipating incurring restructuring and related charges of $33 in fiscal 2026 and the consolidation is expected to be completed by the third quarter of fiscal 2026.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Severance and related benefit costs <sup>(1)</sup> | $(1.2) | $(0.3) |
| Asset write-off and accelerated depreciation | 0.7 |  |
| Other associated exit costs to close and consolidate facilities <sup>(4)</sup> | 13.2 | 2.1 |
| Total restructuring and related charges <sup>(2) (3)</sup> | $12.7 | $1.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Due to natural workforce attrition, the Company recorded an adjustment for the three months ended December 31, 2025 to the severance accrual as of September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Restructuring and related charges of $4.5 and nil are included within Cost of products sold for the three months ended December 31, 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) The Company does not include restructuring and related charges in the results of its reportable segments; however, these charges are related to the Wet Shave segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Includes costs to remove and transport inventory; disassemble, transport and reassemble manufacturing equipment; and other idle facility, contract related and personnel costs.

------

***Consolidation of Wet Shave Operations***

In fiscal 2026, the Company announced a plan to further consolidate its Wet Shave operations. These actions further streamline the Company's operations and supply chain. As a result of these actions, the Company is anticipating incurring restructuring and related charges of $25 in fiscal 2026 and the consolidation is expected to be completed by the first quarter of fiscal 2028.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Severance and related benefit costs  | $8.2 | $— |
| Asset write-off and accelerated depreciation | 1.3 |  |
| Total restructuring and related charges <sup>(1) (2)</sup> | $9.5 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Restructuring and related charges of $1.3 are included within Cost of products sold for the three months ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The Company does not include restructuring and related charges in the results of its reportable segments; however, these charges are related to the Wet Shave segment.

***Restructuring Reserves***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Operating Model Redesign** | **Consolidation of Mexico Facilities** | **Consolidation of Wet Shave Operations** | **Total** |
| <u>Severance and related benefit costs</u> |  |  |  |  |
| Balance at September 30, 2025 | $2.7 | $13.3 | $— | $16.0 |
| Charge to income | 0.3 | (1.2) | 8.2 | 7.3 |
| Cash payments | (1.0) | (4.6) |  | (5.6) |
| Non-cash utilization |  | (0.1) |  | (0.1) |
| Balance at December 31, 2025 | 2.0 | 7.4 | 8.2 | 17.6 |
| <u>Asset write-off and accelerated depreciation</u> |  |  |  |  |
| Balance at September 30, 2025 |  |  |  |  |
| Charge to income |  | 0.7 | 1.3 | 2.0 |
| Non-cash utilization |  | (0.7) | (1.3) | (2.0) |
| Balance at December 31, 2025 |  |  |  |  |
| <u>Other associated exit costs to close and consolidate facilities</u> |  |  |  |  |
| Balance at September 30, 2025 |  | 0.7 |  | 0.7 |
| Charge to income | 1.9 | 13.2 |  | 15.1 |
| Cash payments | (1.9) | (14.0) |  | (15.9) |
| Balance at December 31, 2025 |  | (0.1) |  | (0.1) |
| Total restructuring and related activities accrual | $2.0 | $7.3 | $8.2 | $17.5 |

---

------

**Note 4 - Income Taxes**

The source of income taxes are below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Loss from continuing operations before income taxes | $(36.9) | $(12.7) |
| Income tax benefit on continuing operations | (7.7) | (2.6) |
| Effective tax rate | 20.9% | 20.6% |

---

For the three months ended December 31, 2025 and 2024, the difference between the federal statutory rate and the effective rate was primarily due to a favorable mix of earnings in lower tax rate jurisdictions.

**Note 5 - (Loss) Earnings per Share**

Basic (loss) earnings per share is based on the weighted-average number of common shares outstanding during the period. Diluted net (loss) earnings per share is based on the number of shares used for the basic (loss) earnings per share calculation, adjusted for the dilutive effect of share options, restricted share equivalent ("RSE") and performance restricted share equivalent ("PRSE") awards.

The following is the reconciliation between the number of weighted-average shares used in the basic and diluted net (loss) earnings per share calculation:&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Basic weighted-average shares outstanding | 46.6 | 48.7 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Options, RSE and PRSE awards |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total dilutive securities |  |  |
| Diluted weighted-average shares outstanding | 46.6 | 48.7 |

---

The following weighted-average common shares were excluded from the calculation of diluted net (loss) earnings per share because the effect of including these awards was antidilutive.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Options, RSE and PRSE awards | 1.6 | 1.4 |

---

**Note 6 - Inventories**

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| **Inventories** | | |
| &nbsp;&nbsp;&nbsp;Raw materials and supplies | $72.2 | $73.9 |
| &nbsp;&nbsp;&nbsp;Work in process | 91.2 | 94.5 |
| &nbsp;&nbsp;&nbsp;Finished products | 297.8 | 265.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventories <sup>(1)</sup> | $461.2 | $433.8 |

---

<sup>(1)</sup> $48.1 and $50.9 of inventories of the Feminine Care business have been classified as assets held for sale as of December 31, 2025 and September 30, 2025, respectively. See Note 2, "Discontinued Operations" for additional information.

------

**Note 7 - Property, Plant and Equipment ("PP&E")** 

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| **Property, Plant and Equipment** | | |
| &nbsp;&nbsp;&nbsp;Land | $16.7 | $16.7 |
| &nbsp;&nbsp;&nbsp;Buildings | 116.2 | 114.8 |
| &nbsp;&nbsp;&nbsp;Machinery and equipment | 980.4 | 984.4 |
| &nbsp;&nbsp;&nbsp;Capitalized software costs | 68.5 | 68.2 |
| &nbsp;&nbsp;&nbsp;Construction in progress | 70.9 | 62.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross property, plant and equipment | 1252.7 | 1246.2 |
| &nbsp;&nbsp;&nbsp;Accumulated depreciation and amortization | (960.2) | (951.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total property, plant and equipment, net <sup>(1)</sup> | $292.5 | $295.0 |

---

<sup>(1)</sup> $73.9 and $74.3 of PP&E of the Feminine Care business have been classified as assets held for sale as of December 31, 2025 and September 30, 2025, respectively. See Note 2, "Discontinued Operations" for additional information.

The components of depreciation expense for PP&E, net and amortization expense for capitalized software costs were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Depreciation expense | $12.6 | $10.7 |
| Amortization expense associated with capitalized software | 0.9 | 1.1 |

---

**Note 8 - Goodwill and Intangible Assets**

The following table sets forth goodwill by segment:

---

| | | | |
|:---|:---|:---|:---|
| | **Wet<br>Shave** | **Sun and Skin <br>Care** | **Total** |
| Gross balance at October 1, 2025 | $1150.6 | $357.5 | $1508.1 |
| Accumulated goodwill impairment | (369.0) | (2.0) | (371.0) |
| Net balance at October 1, 2025<sup>(1)</sup> | $781.6 | $355.5 | $1137.1 |
| Changes in the twelve months ended December 31, 2025 |  |  |  |
| Cumulative translation adjustment | 0.3 |  | 0.3 |
| Gross balance at December 31, 2025 | $1150.9 | $357.5 | $1508.4 |
| Accumulated goodwill impairment | (369.0) | (2.0) | (371.0) |
| Net balance at December 31, 2025<sup>(1)</sup> | $781.9 | $355.5 | $1137.4 |

---

<sup>(1)</sup> $117.0 and $154.0 of goodwill of the Feminine Care segment has been classified as assets held for sale as of December 31, 2025 and September 30, 2025, respectively. See Note 2, "Discontinued Operations" for additional information.

------

The following table sets forth intangible assets by class:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** |
| | **Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net** | **Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net** |
| **Indefinite lived** | | | | | | |
| Trade names and brands | $571.4 | $— | $571.4 | $571.4 | $— | $571.4 |
| **Amortizable** |  |  |  |  |  |  |
| Trade names and brands | $237.1 | $80.1 | $157.0 | $237.1 | $77.4 | $159.7 |
| Technology and patents | 80.2 | 78.6 | 1.6 | 80.2 | 78.4 | 1.8 |
| Customer related and other | 266.6 | 174.8 | 91.8 | 266.5 | 171.2 | 95.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortizable intangible assets | 583.9 | 333.5 | 250.4 | 583.8 | 327.0 | 256.8 |
| **Total intangible assets** <sup>(1)</sup> | $1155.3 | $333.5 | $821.8 | $1155.2 | $327.0 | $828.2 |

---

<sup>(1)</sup> $92.7 and $93.1 of intangible assets of the Feminine Care business have been classified as assets held for sale as of December 31, 2025 and September 30, 2025, respectively. See Note 2, "Discontinued Operations" for additional information.

Amortization expense was $6.4 and $6.4 for the three months ended December 31, 2025 and 2024, respectively. Estimated amortization expense for amortizable intangible assets is as follows:

---

| | |
|:---|:---|
| | **Estimated amortization expense** |
| Remainder of fiscal year 2026 | $18.9 |
| 2027 | 25.1 |
| 2028 | 25.0 |
| 2029 | 25.0 |
| 2030 | 25.0 |
| 2031 | 18.0 |
| Thereafter | 113.4 |

---

Goodwill and intangible assets deemed to have an indefinite life are not amortized but are instead reviewed annually for impairment or when indicators of a potential impairment are present. The Company's annual impairment testing date is July 1. An interim impairment analysis may indicate that carrying amounts of goodwill and other intangible assets require adjustment or that remaining useful lives should be revised. The Company continuously monitors events which could trigger an interim impairment analysis, such as changing business conditions, our financial performance and our market capitalization. The Company determined that there were no triggering events requiring an interim impairment analysis during the three months ended December 31, 2025 for its Wet Shave, Sun Care and Skin Care reporting units. See Note 2 for additional information on the Feminine Care reporting unit.

------

**Note 9 - Supplemental Balance Sheet Information**

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| **Other Current Assets** | | |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | $75.8 | $69.8 |
| &nbsp;&nbsp;&nbsp;Value added tax receivables | 45.5 | 43.7 |
| &nbsp;&nbsp;&nbsp;Income taxes receivable | 28.4 | 13.3 |
| &nbsp;&nbsp;&nbsp;Other | 11.9 | 11.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other current assets | $161.6 | $138.6 |
| **Other Current Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Accrued advertising and sales promotion | $29.9 | $23.6 |
| &nbsp;&nbsp;&nbsp;Accrued trade allowances | 22.3 | 27.6 |
| &nbsp;&nbsp;&nbsp;Accrued salaries, vacations and incentive compensation | 33.8 | 52.9 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 13.0 | 20.3 |
| &nbsp;&nbsp;&nbsp;Returns reserve | 29.1 | 42.8 |
| &nbsp;&nbsp;&nbsp;Accrued interest | 9.7 | 24.7 |
| &nbsp;&nbsp;&nbsp;Restructuring reserve | 8.6 | 16.7 |
| &nbsp;&nbsp;&nbsp;Other | 101.5 | 102.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other current liabilities | $247.9 | $311.1 |
| **Other Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Pensions and other retirement benefits | $30.9 | $32.7 |
| &nbsp;&nbsp;&nbsp;Other | 114.2 | 102.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other liabilities | $145.1 | $135.6 |

---

<sup>(1)</sup> $8.9 and $8.7 of other current assets and $4.0 and $5.2 of other current liabilities of the Feminine Care business has been classified as assets held for sale as of December 31, 2025 and September 30, 2025, respectively. See Note 2, "Discontinued Operations" for additional information.

**Note 10 - Accounts Receivable Facilities**

The Company participates in accounts receivable facility programs both in the United States and Japan. These receivable agreements are between the Company and MUFG Bank, LTD ("MUFG"), and the subsidiaries of both parties. Transfers under the accounts receivable repurchase agreements are accounted for as sales of accounts receivables, resulting in the receivables being derecognized from the Condensed Consolidated Balance Sheets. MUFG, as the purchaser, assumes the credit risk at the time of sale and has the right at any time to assign, transfer, or participate any of its rights under the purchased receivables to another bank or financial institution. The purchase and sale of receivables under accounts receivable repurchase agreements is intended to be an absolute and irrevocable transfer without recourse by the purchaser to the Company for the creditworthiness of any obligor. The Company has considered its performance obligation to collect and service the receivables sold in the United States and Japan and has determined that the costs associated with such services are not material. The Company has deemed the compensation received acceptable servicing compensation and as such, the Company does not recognize a servicing asset or liability.

Accounts receivables sold were $221.6 and $223.9 for the three months ended December 31, 2025 and 2024, respectively. The trade receivables sold that remained outstanding as of December 31, 2025 and September 30, 2025 were $91.6 and $94.7, respectively. The net proceeds received were included in both Cash provided by operating activities and Cash used by investing activities on the Condensed Consolidated Statements of Cash Flows. The subsequent cash collections and remittances of cash to MUFG for receivables serviced by the Company are considered financing cash flow activity and are presented net for the period. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in Other (income) expense, net in the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income. The loss on sale of trade receivables was $1.1 for both the three months ended December 31, 2025 and 2024.

------

**Note 11 - Debt**

The detail of long-term debt was as follows:

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| Senior notes, fixed interest rate of 5.5%, due 2028 | $750.0 | $750.0 |
| Senior notes, fixed interest rate of 4.1%, due 2029 | 500.0 | 500.0 |
| U.S. Revolving Credit Facility | 277.0 | 140.0 |
| Total | 1527.0 | 1390.0 |
| Less unamortized debt issuance costs and discount <sup>(1)</sup>  | 6.2 | 6.7 |
| **Total long-term debt** | $1520.8 | $1383.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)As of December 31, 2025, debt issuance costs were $3.6 and $2.6 related to the Senior Notes due 2028 and the Senior Notes due 2029, respectively. As of September 30, 2025, debt issuance costs were $3.9 and $2.8 related to the Senior Notes due 2028 and the Senior Notes due 2029, respectively.

As of December 31, 2025 and September 30, 2025, the Company had outstanding short-term notes payable with financial institutions with original maturities of less than 90 days of $32.5 and $29.5, respectively, with weighted-average interest rates of 3.7% and 3.7% as of December 31, 2025 and September 30, 2025, respectively. These notes were primarily outstanding international borrowings.

**Note 12 - Supply Chain Financing Programs**

The Company has agreements with its suppliers in the ordinary course of business for such supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company's obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers' decisions to finance amounts under these arrangements. The payment terms under the programs range from 60 to 120 days. The obligations are presented as Accounts payable on the Condensed Consolidated Balance Sheets.

The summary of the Company's outstanding obligations confirmed as valid under the SCF program is as follows.

---

| | |
|:---|:---|
| | Fiscal 2026 |
| Confirmed obligations outstanding as of September 30, 2025 | $15.1 |
| Invoices confirmed | 20.7 |
| Invoices Paid | (19.6) |
| Confirmed obligations outstanding as of December 31, 2025 | $16.2 |

---

------

**Note 13 - Retirement Plans**

The Company has several defined benefit pension plans covering employees in the U.S. and certain employees in other countries. The plans provide retirement benefits based on years of service and compensation. The Company also sponsors or participates in several other non-U.S. pension and postretirement arrangements, including various retirement and termination benefit plans, some of which are required by local law or coordinated with government-sponsored plans, which are not significant in the aggregate and, therefore, are not included in the information presented below.

The Company's net periodic pension and postretirement costs for its material plans were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Service cost | $0.5 | $0.6 |
| Interest cost | 4.5 | 4.5 |
| Expected return on plan assets | (5.9) | (5.4) |
| Recognized net actuarial loss | 0.7 | 0.6 |
| Net periodic (benefit) cost | $(0.2) | $0.3 |

---

The service cost component of the net periodic cost associated with the Company's retirement plans is recorded to Cost of products sold and SG&A on the Condensed Consolidated Statement of Earnings and Comprehensive (Loss) Income. The remaining net periodic cost is recorded to Other (income) expense, net on the Condensed Consolidated Statement of Earnings and Comprehensive (Loss) Income.

**Note 14 - Shareholders' Equity**

*Share Repurchases*

On November 13, 2025, the Board approved an authorization to repurchase up to $100.0, superseding the previous share repurchase authorization from January 2018, when the Board approved an authorization to repurchase up to 10.0 shares of the Company's common stock. The full $100.0 authorized by the Board in November 2025 is available for future share repurchases. Any future share repurchases would be made in the open market, privately negotiated transactions or otherwise, in such amounts and at such times as the Company deems appropriate based upon prevailing market conditions, business needs and other factors. The Company did not repurchase any shares of its common stock during the three months ended December 31, 2025.

*Dividends*

Dividend activity in the three months ended December 31, 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Date Declared** | **Record Date** | **Payable Date** | **Amount Per Share** |
| August 5, 2025 | September 4, 2025 | October 8, 2025 | $0.15 |
| November 13, 2025 | December 3, 2025 | January 8, 2026 | $0.15 |

---

On February 5, 2026, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter of 2026. The dividend will be payable on April 8, 2026 to shareholders of record as the close of business on March 6, 2026.

Dividends declared during the three months ended December 31, 2025 totaled $7.0. Payments made for dividends during the three months ended December 31, 2025 totaled $7.4.

------

**Note 15 - Accumulated Other Comprehensive Loss**

The following table presents the changes in Accumulated Other Comprehensive (Loss) Income ("AOCI"), net of tax, by component:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Foreign<br>Currency<br>Translation<br>Adjustments** | **Pension and <br>Post-retirement <br>Activity** | **Hedging<br>Activity** | **Total** |
| Balance as of October 1, 2025 | $(41.3) | $(67.6) | $(0.9) | $(109.8) |
| Other comprehensive income (loss), net of tax | 3.2 | 0.1 | 1.5 | 4.8 |
| Reclassifications to earnings |  | 0.5 |  | 0.5 |
| Balance as of December 31, 2025 | $(38.1) | $(67.0) | $0.6 | $(104.5) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Foreign<br>Currency<br>Translation<br>Adjustments** | **Pension and <br>Post-retirement <br>Activity** | **Hedging<br>Activity** | **Total** |
| Balance as of October 1, 2024 | $(68.3) | $(84.8) | $(1.7) | $(154.8) |
| Other comprehensive income (loss), net of tax | (48.3) | (0.1) | 5.4 | (43.0) |
| Reclassifications to earnings |  | 0.5 | (0.4) | 0.1 |
| Balance as of December 31, 2024 | $(116.6) | $(84.4) | $3.3 | $(197.7) |

---

The following table presents the reclassifications out of AOCI:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Affected Line Item in the <br>Condensed Consolidated <br>Statements of Earnings** |
| **Details of AOCI Components** | **2025** | **2024** | **Affected Line Item in the <br>Condensed Consolidated <br>Statements of Earnings** |
| **Gain on cash flow hedges** |  |  |  |
| Foreign exchange contracts | $(0.1) | $0.5 | Other (income) expense, net |
| Income tax (benefit) expense | (0.1) | 0.1 | Income tax benefit on continuing operations |
|  | $— | $0.4 |  |
| **Amortization of defined benefit pension and postretirement items** |  |  |  |
| Actuarial losses <sup>(1)</sup> | $(0.7) | $(0.6) |  |
| Income tax (benefit) | (0.2) | (0.1) | Income tax benefit on continuing operations |
|  | (0.5) | (0.5) |  |
| Total reclassifications for the period | $(0.5) | $(0.1) |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)These AOCI components are included in the computation of net periodic cost. See Note 13 of Notes to Condensed Consolidated Financial Statements.

------

**Note 16 - Financial Instruments and Risk Management**

In the ordinary course of business, the Company may enter into contractual arrangements (also referred to as derivatives) to reduce its exposure to foreign currency. The Company has master netting agreements with certain of its counterparties as set forth in detail below that allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default. The Company manages counterparty risk through the utilization of investment grade commercial banks, diversification of counterparties, and its counterparty netting arrangements. The section below outlines the types of derivatives in place as of December 31, 2025 and September 30, 2025, as well as the Company's objectives and strategies for holding derivative instruments.

***Foreign Currency Risk***

A significant share of the Company's sales is tied to currencies other than the U.S. dollar, the Company's reporting currency. As such, a weakening of currencies relative to the U.S. dollar can have an unfavorable impact on reported earnings. Conversely, strengthening of currencies relative to the U.S. dollar can improve reported results. The primary currencies to which the Company is exposed include the euro, the Japanese yen, the British pound, the Canadian dollar, and the Australian dollar.

Additionally, the Company's foreign subsidiaries enter into internal and external transactions that create non-functional currency balance sheet positions at the foreign subsidiary level. These exposures are generally the result of intercompany purchases, intercompany loans and, to a lesser extent, external purchases, and are revalued in the foreign subsidiary's local currency at the end of each month. Changes in the value of the non-functional currency balance sheet positions in relation to the foreign subsidiary's local currency results in an exchange gain or loss recorded in Other (income) expense, net in the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income. The primary currency to which the Company's foreign subsidiaries are exposed is the U.S. dollar.

***Interest Rate Risk***

The Company has interest rate risk with respect to interest expense on variable rate debt. As of December 31, 2025, the Company had $277.0 of variable rate debt outstanding, which consisted primarily of outstanding borrowings under its U.S. Revolving Credit Facility.

***Cash Flow Hedges***

As of December 31, 2025, the Company maintains a cash flow hedging program related to foreign currency risk. These derivative instruments have a high correlation to the underlying exposure being hedged and have been deemed highly effective by the Company for accounting purposes in offsetting the associated risk.

The Company has forward currency contracts to hedge cash flow uncertainty associated with currency fluctuations. These transactions are accounted for as cash flow hedges. The Company had unrealized pre-tax gains of $0.8 and unrealized pre-tax losses of $1.4 as of December 31, 2025 and September 30, 2025, respectively, on these forward currency contracts, which are accounted for as cash flow hedges and included in AOCI in the Condensed Consolidated Balance Sheets. Assuming foreign exchange rates versus the U.S. dollar remain at December 31, 2025 levels over the next 12 months, the majority of the pre-tax losses included in AOCI in the Condensed Consolidated Balance Sheets as of December 31, 2025 is expected to be included in Other (income) expense, net in the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income. Contract maturities for these hedges extend into fiscal 2027. As of December 31, 2025, there were 64 open foreign currency contracts with a total notional value of $122.1.

***Derivatives not Designated as Hedges*** 

The Company has foreign currency derivative contracts, which are not designated as cash flow hedges for accounting purposes, to hedge balance sheet exposures. Any gains or losses on these contracts are expected to be offset by exchange gains or losses on the underlying exposures and, thus, are not expected to be subject to significant market risk. The change in the estimated fair value of the foreign currency contracts for the three months ended December 31, 2025, resulted in a gain of $0.6 compared to a gain of $0.9 for the three months ended December 31, 2024, and was recorded in Other (income) expense, net in the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income. As of December 31, 2025, there was one open foreign currency derivative contract not designated as a cash flow hedge with a total notional value of $9.0.

------

The following table provides estimated fair values of derivative instruments:

---

| | | |
|:---|:---|:---|
| | **Fair Value of Assets (Liabilities) as of** <sup>(1)</sup> | **Fair Value of Assets (Liabilities) as of** <sup>(1)</sup> |
| | **December 31,<br>2025** | **September 30,<br>2025** |
| ***Derivatives designated as cash flow hedging relationships:*** | | |
| &nbsp;&nbsp;&nbsp;Foreign currency contracts | $0.8 | $(1.4) |
| ***Derivatives not designated as cash flow hedging relationships:*** |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency contracts | $— | $0.1 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Derivative assets are presented in Other current assets or Other assets. Derivative liabilities are presented in Other current liabilities or Other liabilities.

The following table provides the pre-tax amounts of gains and losses on derivative instruments:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| ***Derivatives designated as cash flow hedging relationships:*** |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency contracts |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) gain recognized in OCI <sup>(1)</sup> | $2.1 | $7.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) gain reclassified from AOCI into income <sup>(1) (2)</sup> | (0.1) | 0.5 |
| ***Derivatives not designated as cash flow hedging relationships:*** |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency contracts |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) gain recognized in income <sup>(2)</sup> | $0.6 | $0.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)(Loss) gain was recorded in Other (income) expense, net in the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income.

The following table provides financial assets and liabilities for balance sheet offsetting:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of September 30, 2025** | **As of September 30, 2025** |
| | **Assets** <sup>(1)</sup> | **Liabilities** <sup>(2)</sup> | **Assets** <sup>(1)</sup> | **Liabilities** <sup>(2)</sup> |
| **Foreign currency contracts** | | | | |
| &nbsp;&nbsp;&nbsp;Gross amounts of recognized assets (liabilities) | $2.2 | $(1.5) | $0.7 | $(2.4) |
| &nbsp;&nbsp;&nbsp;Gross amounts offset in the balance sheet |  | 0.1 |  | 0.3 |
| &nbsp;&nbsp;Net amounts of assets (liabilities) presented in the balance sheet | $2.2 | $(1.4) | $0.7 | $(2.1) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)All derivative assets are presented in Other current assets or Other assets on the Condensed Consolidated Balance Sheets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)All derivative liabilities are presented in Other current liabilities or Other liabilities on the Condensed Consolidated Balance Sheets.

***Fair Value Hierarchy*** 

Accounting guidance on fair value measurements for certain financial assets and liabilities requires that assets and liabilities carried at fair value be classified in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity's own assumptions or external inputs from inactive markets.

------

The following table sets forth the Company's financial assets and liabilities, which are carried at fair value and measured on a recurring basis during the period, all of which are classified as Level 2 within the fair value hierarchy:

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| **Assets (Liabilities) at estimated fair value:** | | |
| Deferred compensation liability | $(21.4) | $(20.7) |
| Derivatives - foreign currency contracts asset (liability) | 0.8 | (1.4) |
| Net assets (liabilities) at estimated fair value | $(20.6) | $(22.1) |

---

The estimated fair value of the deferred compensation liability is determined based upon the quoted market prices of the investment options that are offered under the plan. As of December 31, 2025 and September 30, 2025, the estimated fair value of foreign currency contracts is the amount that the Company would receive or pay to terminate the contracts, considering first the quoted market prices of comparable agreements or, in the absence of quoted market prices, factors such as interest rates, currency exchange rates, and remaining maturities.

As of December 31, 2025 and September 30, 2025, the Company had no Level 1 financial assets or liabilities, other than pension plan assets, and no Level 3 financial assets or liabilities.

As of December 31, 2025 and September 30, 2025, the fair market value of fixed rate long-term debt was $1,196.8 and $1,198.2, respectively, compared to its carrying value of $1,250.0 in each period. The estimated fair value of the long-term debt was estimated using yields obtained from independent pricing sources for similar types of borrowing arrangements which has been determined based on Level 2 inputs.

Due to the nature of cash and cash equivalents and short-term borrowings, including notes payable, the carrying amounts on the Condensed Consolidated Balance Sheets approximate fair value. Additionally, the carrying amounts of the U.S. Revolving Credit Facility, which are classified as long-term debt on the balance sheet, approximate fair value due to the revolving nature of the balances.

**Note 17 - Segment Data**

The reportable segments are organized based on products and were determined in accordance with how our Chief Executive Officer, who is our chief operating decision maker ("CODM"), develops and executes global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses.

The Company's operating model includes some shared business functions across the segments, including product warehousing and distribution, transaction processing functions and, in most cases, a combined sales force and management teams. The Company applies a fully allocated cost basis, in which shared business functions are allocated among the segments. Such allocations are estimates and do not represent the costs of such services if performed on a stand-alone basis.

The measure of segment performance utilized by our CODM is segment profit. Segment profit excludes general corporate expenses and overheads; intangible amortization expense; interest and other expense, net; restructuring and related costs, including impairment charges; and certain U.S. GAAP items that management does not believe are indicative of ongoing operating performance due to their unusual or non-recurring nature and which may have a disproportionate positive or negative impact on the Company's financial results in any particular period. The exclusion of such charges from segment results reflects how the CODM monitors and evaluates segment operating performance, generates future operating plans and makes strategic decisions regarding the allocation of capital.

The accounting policies of the segment are the same as those described in the summary of significant accounting policies disclosed in the Form 10-K. Accounting policies have been applied consistently by all segments within the Company for all reporting periods.

Our CODM is not regularly provided and does not use assets by segment to evaluate performance or allocate resources. Therefore, we do not disclose assets by segment.

The primary source of income for each segment is as described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products.

See Note 1 and Note 2 for additional information on the divestiture of Feminine Care, a previously reportable segment.

------

Segment net sales and profitability are presented below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| **Net Sales** |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $291.3 | $294.5 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | 131.5 | 120.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total net sales** | $422.8 | $415.1 |
| **Cost of Products Sold** |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $171.6 | $166.2 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | 82.8 | 74.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total cost of products sold** | $254.4 | $240.4 |
| **Other operating expenses** <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $77.5 | $81.7 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | 52.3 | 49.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total other operating expenses** | $129.8 | $131.5 |
| **Segment Profit (Loss)** |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $42.2 | $46.6 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | (3.6) | (3.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total segment profit** | $38.6 | $43.2 |
| &nbsp;&nbsp;General corporate and other expenses <sup>(2)</sup> | $(24.1) | $(20.9) |
| &nbsp;&nbsp;&nbsp;Amortization of intangibles | (6.4) | (6.4) |
| &nbsp;&nbsp;&nbsp;Interest and other expense, net | (20.0) | (21.1) |
| &nbsp;&nbsp;Restructuring and related charges <sup>(3)</sup> | (24.4) | (4.1) |
| &nbsp;&nbsp;Acquisition and integration costs <sup>(4)</sup> |  | (0.5) |
| &nbsp;&nbsp;Sun Care reformulation costs <sup>(5)</sup> | (1.0) | (1.0) |
| &nbsp;&nbsp;Legal matters <sup>(6)</sup> | (1.0) |  |
| &nbsp;&nbsp;Gain on investment <sup>(7)</sup> | 1.5 | 0.9 |
| &nbsp;&nbsp;Other project and related costs <sup>(8)</sup> | (0.1) | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Loss from continuing operations before income taxes** | $(36.9) | $(12.7) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Includes SG&A, A&P and R&D costs, which are not regularly provided to the CODM by segment, but included within the measure of segment profit reviewed by the CODM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Includes indirect expenses for corporate overhead in the three months ended December 31, 2025 and 2024 previously allocated to Feminine Care segment profit, which remain reported within continuing operations following the divestiture and are not reallocated to the Wet Shave or Sun and Skin Care segments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The Company recorded $24.4 and $4.1 for the three months ended December 31, 2025 and 2024, respectively, related to actions to strengthen its operating model and improve manufacturing and supply chain efficiency and productivity. Includes pre-tax SG&A of $0.5 and nil for the three months ended December 31, 2025 and 2024, respectively. Includes pre-tax Cost of products sold of $5.8 for the three months ended December 31, 2025 related to other associated disposal costs and accelerated depreciation of certain assets. See Note 3 of the Notes to Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Includes pre-tax SG&A of $0.5 for three months ended December 31, 2024 for the acquisition of Billie, Inc. on November 29, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Includes pre-tax research and development costs of $1.0 and $1.0 for the three months ended December 31, 2025 and 2024, respectively, related to the reformulation, recall and destruction of certain Sun Care products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Includes pre-tax SG&A of $1.0 in the three months ended December 31, 2025, for a charge related to a legal matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Includes pre-tax gain of $1.5 and $0.9 for the three months ended December 31, 2025 and 2024 on the fair value measurement of equity interests accounted for under the cost method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)Includes pre-tax SG&A of $0.6 and $1.0 for the three months ended December 31, 2025 and 2024, respectively, and Other income of $0.5 and other expense $1.8 for the three months ended December 31 2025, respectively, related to certain corporate project and other related costs.

------

Depreciation expense and capital spending by segment were:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| **Depreciation and amortization expense** |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $10.4 | $9.5 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | 1.5 | 1.8 |
| &nbsp;&nbsp;&nbsp;Corporate | 8.1 | 6.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total depreciation and amortization expense** <sup>(1)</sup> | $20.0 | $18.1 |
| **Capital expenditures** |  |  |
| &nbsp;&nbsp;&nbsp;Wet Shave | $8.5 | $10.7 |
| &nbsp;&nbsp;&nbsp;Sun and Skin Care | 2.7 | 4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total capital expenditures** <sup>(2)</sup> | $11.2 | $15.4 |

---

<sup>(1)</sup> $1.3 and $3.6 of Depreciation and amortization expense of the Feminine Care business have been classified as (Loss) earnings from discontinued operations, net of tax as of December 31, 2025 and 2024, respectively. See Note 2, "Discontinued Operations" for additional information.

<sup>(2)</sup> $0.4 and $1.4 of capital expenditures of the Feminine Care business have been classified as (Loss) earnings from discontinued operations, net of tax as of December 31, 2025 and 2024, respectively. See Note 2, "Discontinued Operations" for additional information.

The following table presents the Company's net sales by geographic area:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| **Net Sales to Customers** |  |  |
| &nbsp;&nbsp;&nbsp;United States | $191.9 | $187.5 |
| &nbsp;&nbsp;&nbsp;International | 230.9 | 227.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total net sales** | $422.8 | $415.1 |

---

Supplemental product information is presented below for net sales:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| Razors and blades | $259.0 | $267.4 |
| Sun care products | 57.2 | 47.4 |
| Grooming products | 57.3 | 53.0 |
| Wipes and other skin care | 17.0 | 20.2 |
| Shaving gels and creams | 32.3 | 27.1 |
| &nbsp;&nbsp;&nbsp;**Total net sales** | $422.8 | $415.1 |

---

------

**Note 18 - Commitments and Contingencies**

***Legal Proceedings***

The Company and its subsidiaries are subject to a number of legal proceedings in various jurisdictions arising out of its operations during the ordinary course of business. Many of these legal matters are in preliminary stages and involve complex issues of law and fact and may proceed for protracted periods of time. The amount of liability, if any, from these proceedings cannot be determined with certainty. The Company reviews its legal proceedings and claims, regulatory reviews and inspections and other legal proceedings on an ongoing basis and follows appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies when the incurrence of a loss is probable and can be reasonably estimated and discloses the amount accrued and the amount of a reasonably possible loss in excess of the amount accrued if such disclosure is necessary for its financial statements to not be misleading. The Company does not record liabilities when the likelihood that the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company believes that its liability, if any, arising from such pending legal proceedings, asserted legal claims, and known potential legal claims which are likely to be asserted, is not reasonably likely to be material to its financial position, results of operations or cash flows, when taking into account established accruals for estimated liabilities.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

(Amounts in millions, except per share data, unaudited)

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the accompanying notes included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the SEC on November 18, 2025 (the "2025 Annual Report"). The following discussion may contain forward-looking statements that reflect our plans, estimates, and beliefs and involve risks, uncertainties, and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed within "Forward-Looking Statements" below and in Item 1A. Risk Factors and "Forward-Looking Statements" included within our 2025 Annual Report.

*Non-GAAP Financial Measures*

While we report financial results in accordance with GAAP, this discussion also includes non-GAAP measures. These non-GAAP measures are referred to as "adjusted" or "organic" and exclude items which are considered by the Company as unusual or non-recurring, and which may have a disproportionate positive or negative impact on the Company's financial results in any particular period. Reconciliations of non-GAAP measures are included within this Management's Discussion and Analysis of Financial Condition and Results of Operations.

This non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. We use this non-GAAP information, including adjusted gross margin, adjusted selling general and administrative ("SG&A"), adjusted operating income, adjusted EBIT (as defined below), adjusted effective tax rate, adjusted net earnings, and adjusted diluted net earnings, internally to make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of ongoing operating results. We view the use of non-GAAP measures that exclude the impact of these unique events as particularly valuable in understanding our underlying operational results and providing insights into future performance. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by the types of items that are excluded. This non-GAAP information is also a component in determining management's incentive compensation. Finally, we believe this information provides more transparency.

The following provides additional detail on our non-GAAP measures for the periods presented:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We analyze net sales and segment profit on an organic basis to better measure the comparability of results between periods. Organic net sales and organic segment profit exclude the impact of changes in foreign currency translation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment profit is impacted by fluctuations in translation and transactional foreign currency. The impact of currency was applied to segments using management's best estimate.

All comparisons are with the same period in the prior year, unless otherwise noted.

*Industry and Market Data*

Unless we indicate otherwise, we base the information contained or incorporated by reference herein, concerning our industry on our general knowledge and expectations. Our market position, market share, and industry market size are estimates based on internal and external data from various industry analyses, our internal research and adjustments, and assumptions that we believe to be reasonable. We have not independently verified data from industry analyses and cannot guarantee its accuracy or completeness. In addition, we believe that industry, market size, market position and market share data within our industry provides general guidance but is inherently imprecise and has not been verified by any independent source. Further, our estimates and assumptions involve risks and uncertainties and are subject to change based on various factors, including those discussed in Item 1A. Risk Factors in Part I of our 2025 Annual Report. These and other factors could cause results to differ materially from those expressed in the estimates and assumptions. You are cautioned not to place undue reliance on this data.

Retail sales for purposes of market size, market position and market share information are based on retail sales in U.S. dollars.

*Trademarks and Trade Names*

We own or have rights to use trademarks and trade names that we use in conjunction with the operation of our business, which appear throughout this Quarterly Report on Form 10-Q. We may also refer to brand names, trademarks, service marks and trade names of other companies and organizations, which are the property of their respective owners.

------

**Executive Summary** 

**Feminine Care Divestiture**

On November 12, 2025, we entered into an agreement to sell our Feminine Care segment to Essity, a leading global health and hygiene company based in Sweden for $340.0. On February 2, 2026, we closed the transaction and received proceeds of approximately $340 million on a cash-free and debt-free basis. In connection with closing of the transaction, we and Essity entered into a transition services agreement for the provision of certain services to support the transition of the Feminine Care segment following the closing. The divestiture of the Feminine Care segment is a key step to transform Edgewell into a more focused, agile and consumer-driven personal care company. In the first quarter of fiscal 2026, the assets and liabilities of the former Feminine Care segment were classified as held for sale and the former Feminine Care segment's results are presented as discontinued operations. This change was applied on a retrospective basis.

All amounts, percentages and disclosures for all periods presented reflect only the continuing operations of Edgewell unless otherwise noted.

***First Quarter of Fiscal* 2026**

The following is a summary of results from continuing operations for the first quarter of fiscal 2026, as compared to the corresponding periods in fiscal 2025. In addition to net sales, net loss from continuing operations and earnings per share ("EPS") from continuing operations for the periods presented were also impacted by certain costs or income, as described in the table below. The impact of these items on reported net loss from continuing operations and EPS from continuing operations are provided as a reconciliation of net loss from continuing operations and EPS from continuing operations to adjusted net loss from continuing operations and adjusted diluted EPS from continuing operations, both of which are non-GAAP measures.

***•*** <u>Net sales</u> in the first quarter of fiscal 2026 increased $7.7, or 1.9%, to $422.8, as compared to the prior year quarter. Organic net sales decreased $1.9, or 0.5%. Organic sales growth in North America was 0.7%, driven by volume growth in Sun Care and Grooming, partially offset by lower volumes and unfavorable pricing in Wet Shave and Skin Care. Organic sales in international markets declined 1.6%, largely driven by volume declines in Sun Care and Wet Shave, primarily reflecting an anticipated change in the quarterly phasing of Wet Shave sales in Japan, and Sun Care sales in distributor markets.

**•** <u>Net (loss) earnings from continuing operations</u> in the first quarter of fiscal 2026 were $(29.2) compared to $(10.1) in the prior year quarter. On an adjusted basis, net (loss) earnings from continuing operations for the first quarter of fiscal 2026 were $(7.6) compared to $(4.8) in the prior year quarter. Adjusted net loss increased primarily due to a decrease in gross margin, partially offset by higher sales.

• <u>Diluted net (loss) earnings per share from continuing operations</u> during the first quarter of fiscal 2026 were $(0.63) compared to $(0.21) in the prior year quarter. On an adjusted basis, diluted net earnings per share from continuing operations during the first quarter of fiscal 2026 were $(0.16) compared to $(0.10) in the prior year quarter.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** | **Three Months Ended December 31, 2025** |
|  | **Gross Profit** | **SG&A** | **Operating (Loss) Income** | **EBIT (Loss) from Continuing Operations** <sup>(1)</sup> | **Income Tax Provision (Benefit) from Continuing Operations** | **Net Loss from Continuing Operations** | **Diluted EPS from Continuing Operations** |
| **GAAP — Reported** | $161 | $102.4 | $(18.9) | $(36.9) | $(7.7) | $(29.2) | $(0.63) |
| Restructuring and related costs | 5.8 | (0.5) | 24.4 | 24.4 | 6.0 | 18.4 | 0.40 |
| Sun Care reformulation costs |  |  | 1.0 | 1.0 | 0.2 | 0.8 | 0.02 |
| Gain on investment |  |  |  | (1.5) | (0.3) | (1.2) | (0.03) |
| Legal matter |  | (1.0) | 1.0 | 1.0 | 0.2 | 0.8 | 0.02 |
| Other project and related costs |  | (0.6) | 0.6 | 0.1 |  | 0.1 |  |
| Tax shortfall on equity compensation |  |  |  |  | (2.7) | 2.7 | 0.06 |
| **Total Adjusted Non-GAAP** | $166.8 | $100.3 | $8.1 | $(11.9) | $(4.3) | $(7.6) | $(0.16) |
| GAAP as a percent of net sales | 38.1% | 24.2% | (4.5)% |  | GAAP effective tax rate | GAAP effective tax rate | 20.9% |
| Adjusted as a percent of net sales | 39.5% | 23.7% | 1.9% |  | Adjusted effective tax rate | Adjusted effective tax rate | 34.7% |

---

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** |
| | **Gross Profit** | **SG&A** | **Operating Income** | **EBIT (Loss) from Continuing Operations** <sup>(1)</sup> | **Income Taxes from Continuing Operations** | **Net Loss from Continuing Operations** | **Diluted EPS from Continuing Operations** |
| **GAAP — Reported** | $172.5 | $99.6 | $9.3 | $(12.7) | $(2.6) | $(10.1) | $(0.21) |
| Restructuring and related costs |  |  | 4.1 | 4.1 | 1.0 | 3.1 | 0.07 |
| Acquisition and integration costs |  | (0.5) | 0.5 | 0.5 | 0.1 | 0.4 | 0.01 |
| Sun Care reformulation costs |  |  | 1.0 | 1.0 | 0.3 | 0.7 | 0.01 |
| Gain on investment |  |  |  | (0.9) |  | (0.9) | (0.02) |
| Other project and related costs |  | (1.0) | 1.0 | 2.8 | 0.8 | 2.0 | 0.04 |
| **Total Adjusted Non-GAAP** | $172.5 | $98.1 | $15.9 | $(5.2) | $(0.4) | $(4.8) | $(0.10) |
| GAAP as a percent of net sales | 41.6% | 24.0% | 2.2% |  | GAAP effective tax rate | GAAP effective tax rate | 20.6% |
| Adjusted as a percent of net sales | 41.6% | 23.6% | 3.8% |  | Adjusted effective tax rate | Adjusted effective tax rate | 7.8% |

---

(1) EBIT is defined as Loss before income taxes.

**Operating Results** 

The following table presents changes in net sales for the first quarter of fiscal 2026, as compared to the corresponding periods in fiscal 2025, and provides a reconciliation of organic net sales to reported amounts.

***Net Sales***

---

| | | |
|:---|:---|:---|
| **Net Sales - Total Company** | | |
| **Period Ended December 31, 2025** | **Q1** | **% Chg** |
| Net sales - fiscal 2025 | $415.1 |  |
| Organic | (1.9) | (0.5)% |
| Impact of currency | 9.6 | 2.4% |
| &nbsp;&nbsp;Net sales - fiscal 2026 | $422.8 | 1.9% |

---

For the first quarter of fiscal 2026, net sales increased $7.7, or 1.9%, to $422.8, including a $9.6, or 2.4%, favorable impact from currency movements, as compared to the prior year quarter. Organic net sales decreased $1.9, or 0.5%. Organic sales growth in North America was 0.7%, driven by volume growth in Sun Care and Grooming, partially offset by lower volumes and unfavorable pricing in Wet Shave and Skin Care. Organic sales in international markets declined 1.6%, largely driven by volume declines in Sun Care and Wet Shave, primarily reflecting an anticipated change in the quarterly phasing of Wet Shave sales in Japan, and Sun Care sales in distributor markets.

***Gross Profit***

Gross profit was $161.0 during the first quarter of fiscal 2026, compared to $172.5 in the prior year quarter, a decrease of $11.5, or 6.7%. Gross margin as a percent of net sales for the first quarter of fiscal 2026 decreased 350-basis points, to 38.1%. Adjusted gross margin, as a percent of net sales, decreased 210-basis points. Productivity savings of approximately 240-basis points and favorable currency movements were more than offset by 450-basis points of core inflation, tariffs, volume absorption and 75-basis points of unfavorable mix and other.

***Selling, General and Administrative Expense***

Selling, general and administrative ("SG&A") expense was $102.4, or 24.2%, of net sales in the first quarter of fiscal 2026 compared to $99.6, or 24.0%, of net sales in the prior year quarter. Adjusted SG&A was 23.7% of net sales, flat to the prior year quarter, which was primarily driven by higher people costs and unfavorable currency impacts, partly offset by lower consulting and corporate expenses.

***Advertising and Sales Promotion Expense***

Advertising and sales promotion ("A&P") expense for the first quarter of fiscal 2026 was $45.6, a decrease of $0.5, or 1.1%, compared to $46.1 in the prior year quarter. A&P was 10.8% of net sales, compared to 11.1% in the prior year quarter.

------

***Research and Development Expense***

Research and development ("R&D") expense for the first quarter of fiscal 2026 was $13.8, an increase of $0.4, or 3.0%, compared to $13.4 in the prior year quarter. As a percentage of net sales, R&D expense was 3.3% in the first quarter of fiscal 2026, compared to 3.2% in the prior year quarter.

***Restructuring and Related Charges***

In fiscal 2026, the Company continues to take specific actions to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency through restructuring actions, including streamlining the Company's operations and supply chain by consolidating its Mexico facilities and Wet Shave operations. As a result of these actions, we expect to incur pre-tax charges of approximately $65 in fiscal 2026. We incurred $18.1 and $4.1 during the first three months of fiscal 2026 and 2025, respectively. Other restructuring related charges of $5.8 and $0.5 associated with the operation and supply chain actions were recorded in costs of products sold and selling, general and administrative expenses, respectively, during the first quarter of fiscal 2026.

See Note 3 to the Condensed Consolidated Financial Statements for additional information.

***Interest Expense Associated with Debt***

Interest expense associated with debt for the first quarter of fiscal 2026 was $19.3, an increase of $0.5, or 2.7%, compared to $18.8 in the prior year quarter. The increase in interest expense was the result of higher borrowing levels on the Company's U.S. Revolving Credit Facility.

***Other (Income) Expense, net***

Other (income) expense, net, was $(1.3) compared to $3.2 in the prior year quarter. Currency hedge and remeasurement losses were $0.9 in the current quarter, compared to losses of $2.0 in the prior year quarter. The current year quarter included $0.5 of other project gains, compared to $1.8 of expense in the prior year quarter. Adjusted other (income) expense, net was $0.7 compared to $2.3 in the prior year quarter.

***Income Tax Benefit on Continuing Operations***

The continuing operations effective tax rate for the first quarter of fiscal 2026, was 20.9%, compared to 20.6% in the prior year quarter. Both periods reflect a tax benefit on a loss. The fiscal 2026 effective tax rate reflects more favorable discrete and unusual items resulting in a larger tax benefit compared to fiscal 2025. On an adjusted basis, the effective tax rate was 34.7% (tax benefit on a loss), up from the prior year quarter adjusted effective tax rate of 7.8% (tax benefit on a loss).

***(Loss) earnings from discontinued operations, net of tax***

(Loss) earnings from discontinued operations, net of tax includes the results of the Feminine Care business that was held-for-sale in the first quarter of fiscal 2026.

The loss of $36.5 in the first quarter of fiscal 2026 compared to earnings of $8.0 in the prior year quarter. The loss in the first quarter of 2026 primarily includes the impact of the goodwill impairment charge of $37.4 and loss on held-for-sale of $3.8.

------

**Segment Results**

The following tables present changes in segment net sales and segment profit (loss) for the first quarter of fiscal 2026, compared to the corresponding period in fiscal 2025, and provide a reconciliation of organic segment net sales and organic segment profit (loss) to reported amounts. For a reconciliation of segment profit (loss) to Loss from continuing operations before income taxes, refer to Note 17 of Notes to Condensed Consolidated Financial Statements.

Our operating model includes some shared business functions across segments, including product warehousing and distribution, transaction processing functions and, in most cases, a combined sales force and management teams. We apply a fully allocated cost basis in which shared business functions are allocated between segments.

***Wet Shave***

---

| | | |
|:---|:---|:---|
| **Net Sales - Wet Shave** | | |
| **Period Ended December 31, 2025** | **Q1** | **% Chg** |
| Net sales - fiscal 2025 | $294.5 |  |
| Organic | (11.6) | (3.9)% |
| Impact of currency | 8.4 | 2.8% |
| &nbsp;&nbsp;Net sales - fiscal 2026 | $291.3 | (1.1)% |

---

Wet Shave net sales for the first quarter of fiscal 2026 were $291.3, a decrease of $3.2, or 1.1%, as compared to the prior year quarter, including a $8.4, or 2.8%, favorable impact from currency. Organic net sales decreased $11.6, or 3.9%, as International markets declined 0.7% as a result of unfavorable phasing of Wet Shave sales in Japan, as anticipated, partly offset by higher pricing while North America declined 8.3% as a result of decreased volumes and increased promotional levels.

---

| | | |
|:---|:---|:---|
| **Segment Profit - Wet Shave** | | |
| **Period Ended December 31, 2025** | **Q1** | **% Chg** |
| Segment profit - fiscal 2025 | $46.6 |  |
| Organic | (8.5) | (18.2)% |
| Impact of currency | 4.1 | 8.8% |
| &nbsp;&nbsp;Segment profit - fiscal 2026 | $42.2 | (9.4)% |

---

Wet Shave segment profit for the first quarter of fiscal 2026 was $42.2, a decrease of $4.4, or 9.4%, and inclusive of a $4.1, or 8.8%, favorable impact from currency. Organic segment profit decreased $8.5 million, or 18.2%, as lower gross margins were partly offset by lower marketing and SG&A expenses.

***Sun and Skin Care***

---

| | | |
|:---|:---|:---|
| **Net Sales - Sun and Skin Care** | | |
| **Period Ended December 31, 2025** | **Q1** | **% Chg** |
| Net sales - fiscal 2025 | $120.6 |  |
| Organic | 9.7 | 8.0% |
| Impact of currency | 1.2 | 1.0% |
| &nbsp;&nbsp;Net sales - fiscal 2026 | $131.5 | 9.0% |

---

Sun and Skin Care net sales for the first quarter of fiscal 2026 increased $10.9, or 9.0%, as compared to the prior year quarter, including a favorable impact from foreign currency of $1.2, or 1.0%. Organic net sales increased $9.7, or 8.0%, driven by 19.5% growth in Sun Care, primarily driven by higher volumes in North America. Grooming increased 6.8% driven by increased volumes, led by nearly 27% growth in Cremo. In aggregate, the increase in organic sales was related to 14.8% growth in North America, partially offset by a 5.4% decline in International sales.

------

---

| | | |
|:---|:---|:---|
| **Segment Profit (Loss) - Sun and Skin Care** | | |
| **Period Ended December 31, 2025** | **Q1** | **% Chg** |
| Segment loss - fiscal 2025 | $(3.4) |  |
| Organic | (0.5) | 14.7% |
| Impact of currency | 0.3 | (8.8)% |
| &nbsp;&nbsp;Segment loss - fiscal 2026 | $(3.6) | 5.9% |

---

Sun and Skin Care segment loss for the first quarter of fiscal 2026 was $3.6, an increase of $0.2, or 5.9%, as compared to the prior year quarter, including a favorable impact from foreign currency of $0.3, or 8.8%. Organic segment loss increased $0.5 million, or 14.7%, driven by higher marketing, partly offset by higher gross profit.

**General Corporate and Other Expenses**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;General corporate and other expenses | $(24.1) | $(20.9) |
| &nbsp;&nbsp;&nbsp;Amortization of intangibles | (6.4) | (6.4) |
| &nbsp;&nbsp;&nbsp;Interest and other expense, net | (20.0) | (21.1) |
| &nbsp;&nbsp;&nbsp;Restructuring and related charges | (24.4) | (4.1) |
| &nbsp;&nbsp;&nbsp;Acquisition and integration costs |  | (0.5) |
| &nbsp;&nbsp;&nbsp;Sun Care reformulation costs | (1.0) | (1.0) |
| &nbsp;&nbsp;&nbsp;Legal matters | (1.0) |  |
| &nbsp;&nbsp;&nbsp;Gain on investment | 1.5 | 0.9 |
| &nbsp;&nbsp;&nbsp;Other project and related costs | (0.1) | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp; General corporate and other expenses | $(75.5) | $(55.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;% of net sales | (17.9)% | (13.5)% |

---

For the first quarter of fiscal 2026, corporate expenses were $75.5, or 17.9%, of net sales, compared to $55.9, or 13.5% in the prior year quarter.

During the first quarter of fiscal 2026, corporate expenses increased primarily related to higher people costs and unfavorable currency impacts, partly offset by lower consulting and corporate expenses. General corporate and other expenses includes indirect corporate overhead costs previously allocated to the Feminine Care segment.

During the first quarter of fiscal 2026, we recorded a charge of $1.0 related to a legal matter.

During the first quarter of fiscal 2026 and 2025, we recorded a gain of $1.5 and $0.9, respectively, for the fair value measurement of certain equity interests accounted for under the cost and equity methods.

------

**Liquidity and Capital Resources**

As of December 31, 2025, a significant portion of our cash balances was located outside the U.S. Given our extensive international operations, a significant portion of our cash is denominated in foreign currencies. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for a discussion of the primary currencies to which the Company is exposed. We manage our worldwide cash requirements by reviewing available funds among the many subsidiaries through which we conduct business and the cost effectiveness with which those funds can be accessed. We generally repatriate a portion of current year earnings from select non-U.S. subsidiaries only if the economic cost of the repatriation is not considered material.

Our cash is deposited with multiple counterparties which consist of major financial institutions. We consistently monitor positions with, and credit ratings of, counterparties both internally and by using outside ratings agencies.

Our total borrowings as of December 31, 2025 and September 30, 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Interest Type** | **Currency** | **December 31,<br>2025** | **September 30,<br>2025** |
| Long-term notes | fixed | USD | $1250.0 | $1250.0 |
| Revolver loans borrowed under the U.S. Revolving Credit Facility | variable | USD | 277.0 | 140.0 |
| Short-term notes payable | variable | various | 32.5 | 29.5 |
| Total borrowings |  |  | $1559.5 | $1419.5 |

---

Our Revolver utilization is summarized below.

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2025** | **September 30,<br>2025** |
| Total Revolver capacity | $425.0 | $425.0 |
| Less: Revolver borrowings | 277.0 | 140.0 |
| Less: Outstanding letters of credit | 5.5 | 5.5 |
| Revolver balance available | $142.5 | $279.5 |

---

As noted above, on February 2, 2026, we closed on the sale of our Feminine Care segment to Essity. We used proceeds from this sale to repay all outstanding borrowings under our Revolver. The remaining proceeds are expected to be used for continued investment in our core brands, capital expenditures and other growth initiatives. We estimate approximately $55 million of cash taxes to be paid on the tax gain from the sale.

Historically, we have generated, and expect to continue to generate, favorable cash flows from operations. Our cash flows are affected by the seasonality of our Sun Care businesses, typically resulting in higher net sales and increased cash generated in the second and third quarters of each fiscal year. We believe our cash on hand, including remaining proceeds from the sale of our Feminine Care segment, cash flows from operations and borrowing capacity under the U.S. Revolving Credit Facility will be sufficient to satisfy our future working capital requirements, interest payments, R&D activities, capital expenditures, and other capital requirements for at least the next 12 months. We will continue to monitor our cash flows, spending and liquidity needs. For more information on the U.S. Revolving Credit Facility and our other debt, see Note 11 to the Notes To Condensed Consolidated Financial Statements and Note 12 of the Notes to Consolidated Financial Statements in our 2025 Annual Report.

Short-term financing needs primarily consist of working capital requirements and interest payments on our long-term debt. Long-term financing needs will depend largely on potential growth opportunities, including acquisition activity and repayment or refinancing of our long-term debt obligations. Our long-term liquidity may be influenced by our ability to borrow additional funds, renegotiate existing debt, and raise equity under terms that are favorable to us. We may, from time-to-time, seek to repurchase shares of our common stock. Such repurchases, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

As of December 31, 2025, we were in compliance with the provisions and covenants associated with our debt agreements.

------

***Cash Flows***

A summary of our cash flow activities is provided in the following table:

---

| | | |
|:---|:---|:---|
| | **Three months ended December 31,** | **Three months ended December 31,** |
| | **2025** | **2024** |
| Net cash provided by (used for) from: |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $(125.9) | $(115.6) |
| &nbsp;&nbsp;&nbsp;Investing activities | (9.9) | (15.7) |
| &nbsp;&nbsp;&nbsp;Financing activities | 133.4 | 109.9 |
| &nbsp;&nbsp;&nbsp;Effect of exchange rate changes on cash |  | (12.2) |
| Net decrease in cash and cash equivalents | $(2.4) | $(33.6) |

---

*<u>Operating Activities</u>*

Cash flow used for operating activities was $125.9 during the first three months of fiscal 2026, compared to $115.6 during the prior year quarter. The increase in cash used for operating activities was largely driven by changes in net working capital and lower earnings.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

*<u>Investing Activities</u>*

Net cash used for investing activities was $9.9 during the first three months of fiscal 2026, compared to $15.7 during the prior year quarter. The decrease in cash used was primarily due to a decrease in capital expenditures, which were $11.6 during the first three months of fiscal 2026, compared to $16.8 in the prior year quarter.

*<u>Financing Activities</u>*

Net cash provided by financing activities was $133.4 during the first three months of fiscal 2026, compared to $109.9 in the prior year quarter. During the first three months of fiscal 2026, we had net borrowings of $137.0 under the U.S. Revolving Credit Facility, compared to net borrowing of $165.0 in the prior year quarter. Dividend payments totaled $7.4 in the first three months of fiscal 2026, compared to $7.9 in the prior year quarter. We had no share repurchases in the first three months of fiscal 2026, compared to $30.3 in the prior year quarter.

***Share Repurchases***

On November 13, 2025, the Board approved an authorization to repurchase for up to $100.0, superseding the previous share repurchase authorization from January 2018, when the Board approved an authorization to repurchase up to 10.0 shares of the Company's common stock. The full $100.0 authorized by the Board in November 2025 is available for future share repurchases. Any future share repurchases, if any, would be made in the open market, privately negotiated transactions or otherwise permitted, and in such amounts and at such times as the Company deems appropriate based upon prevailing market conditions, business needs and other factors. During the first three months of fiscal 2026, we did not repurchase any shares under the share repurchase plan. For more information, see Note 14 of the Notes to Condensed Consolidated Financial Statements.

------

***Dividends***

Dividend activity for the three months ended December 31, 2025 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Date Declared** | **Record Date** | **Payable Date** | **Amount Per Share** |
| August 5, 2025 | September 4, 2025 | October 8, 2025 | $0.15 |
| November 13, 2025 | December 3, 2025 | January 8, 2026 | $0.15 |

---

On February 5, 2026, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter of 2026. The dividend will be payable on April 8, 2026 to shareholders of record as the close of business on March 6, 2026.

Dividends declared during the three months ended December 31, 2025 totaled $7.0. Payments made for dividends during the three months ended December 31, 2025 totaled $7.4.

***Commitments and Contingencies***

*Contractual Obligations*

As of December 31, 2025, we had outstanding borrowings of $277.0 under the U.S. Revolving Credit Facility, which matures in 2029. As noted above, following the closing of the sale of the Feminine Care segment, we repaid all outstanding borrowings under the U.S. Revolving Credit Facility. As of December 31, 2025, future minimum repayments of fixed debt are: $750.0 in fiscal 2028 and $500.0 in fiscal 2029.

There have been no other material changes in our contractual obligations since the presentation in our 2025 Annual Report.

***Recent Accounting Pronouncements***

Information regarding new accounting pronouncements is included in Note 1 of the Notes to Condensed Consolidated Financial Statements.

***Critical Accounting Estimates***

Our critical accounting estimates are fully described in our 2025 Annual Report. The preparation of these financial statements requires us to make estimates and assumptions. These estimates and assumptions can be subjective and complex, and consequently, actual results could differ from those estimates. There have been no significant changes to our critical accounting estimates since September 30, 2025.

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

(Amounts in millions)

The market risk inherent in our financial instruments and positions represents the potential loss arising from adverse changes in currency rates, commodity prices, and interest rates. At times, we enter into contractual arrangements (derivatives) to reduce these exposures. For further information on our foreign currency derivative instruments, refer to Note 16 of Notes to our Condensed Consolidated Financial Statements.

As of December 31, 2025, there were no open derivative or hedging instruments for future purchases of raw materials or commodities.

Our exposure to interest rate risk relates primarily to our variable-rate debt instruments, which currently bear interest based on Secured Overnight Financing Rate (SOFR) plus margin. As of December 31, 2025, our outstanding variable-rate debt included $308.4 related to the U.S. Revolving Credit Facility and international, variable-rate notes payable. Assuming a one-percent increase in the applicable interest rates, annual interest expense on these variable-rate debt instruments would increase approximately $3.1.

There have been no material changes in our assessment of market risk sensitivity since our presentation of Quantitative and Qualitative Disclosures About Market Risk in our 2025 Annual Report.

**Item 4. Controls and Procedures.**

***Evaluation of Disclosure Controls and Procedures***

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2025. Based on that evaluation, our CEO and CFO concluded that, as of that date, our disclosure controls and procedures were effective.

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are likely to materially affect, our internal control over financial reporting.

------

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings.**

Please see Note 18 of the Notes to Condensed Consolidated Financial Statements for information regarding legal proceedings to which we are party.

**Item 1A. Risk Factors.**

For a discussion of potential risks and uncertainties related to us, see the information included in Part I, Item 1A, "Risk Factors" of our 2025 Annual Report. There have been no material changes to the risk factors disclosed in our 2025 Annual Report.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.**

The following table sets forth the purchases of our Company's securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the first quarter of fiscal 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | <br>**Total Number of**<br> **Shares Purchased** <sup>(1)</sup> | <br>**Average Price Paid**<br> **per share** <sup>(2)</sup> | **Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs** | **Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs** <sup>(3)</sup> |
| October 1 to 31, 2025 |  | $— |  | 226,694 shares |
| November 1 to 30, 2025 | 150169 | $18.71 |  | $100000000 |
| December 1 to 31, 2025 | 798 | $17.00 |  | $100000000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)There were 150,967 shares purchased during the quarter related to the surrender of shares of common stock to our Company to satisfy tax withholding obligations in connection with the vesting of restricted stock equivalents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Includes $0.02 per share of brokerage fee commissions and excludes excise tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)On November 13, 2025, the Board approved an authorization to repurchase for up to $100.0, superseding the previous share repurchase authorization from January 2018, when the Board approved an authorization to repurchase up to 10.0 shares of the Company's common stock. For more information, see Note 14 of the Notes To Condensed Consolidated Financial Statements.

**Item 5. Other Information.**

(a) None.

(b) None.

(c) During the three months ended December 31, 2025, no directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated a "Rule 10b5-1 trading arrangement" and/or "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K.

------

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit** |
| 2.1^† | <u>[Asset Purchase Agreement, dated as of November 12, 2025, by and between Edgewell Personal Care Company and Essity Aktiebolag (publ) (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed November 13, 2025).](https://www.sec.gov/Archives/edgar/data/1096752/000162828025051814/exhibit21finalformatteddoc.htm)</u> |
| 3.1 | <u>[Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2013).](https://www.sec.gov/Archives/edgar/data/1096752/000109675214000021/enr10q123113ex31.htm)</u> |
| 3.2 | <u>[Articles of Merger effective June 30, 2015 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed July 1, 2015).](https://www.sec.gov/Archives/edgar/data/1096752/000119312515242462/d40769dex31.htm)</u> |
| 3.3 | <u>[Amended and Restated Bylaws of the Company effective November 5, 2020 (incorporated by reference to Exhibit 3.3 to the Company's Annual Report on Form 10-K filed November 20, 2020).](https://www.sec.gov/Archives/edgar/data/1096752/000109675220000059/epc10-k93020ex33.htm)</u> |
| 31.1\* | <u>[Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](epc10q12312025ex311.htm)</u> |
| 31.2\* | <u>[Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](epc10q12312025ex312.htm)</u> |
| 32.1\*\* | <u>[Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](epc10q12312025ex321.htm)</u> |
| 32.2\*\* | <u>[Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](epc10q12312025ex322.htm)</u> |
| 101 | The following materials from the Edgewell Personal Care Company Quarterly Report on Form 10-Q formatted in inline eXtensible Business Reporting Language ("iXBRL"): (i) the Condensed Consolidated Statements of Earnings and Comprehensive (Loss) Income for the three months ended December 31, 2025 and 2024, (ii) the Condensed Consolidated Balance Sheets at December 31, 2025 and September 30, 2025, (iii) the Condensed Consolidated Statements of Cash Flows for the three months ended December 31, 2025 and 2024, (iv) the Condensed Consolidated Statements of Shareholder's Equity for the three months ended December 31, 2025 and 2024 and (v) Notes to Condensed Consolidated Financial Statements. The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." |
| 104\* | Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document). |

---

\* Filed herewith.

\*\* Furnished herewith.

^ Copies of schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission or its staff.

† Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | EDGEWELL PERSONAL CARE COMPANY | EDGEWELL PERSONAL CARE COMPANY |
| | | Registrant | Registrant |
| | | By: | /s/ Francesca Weissman |
| | | | Francesca Weissman |
| | | | Chief Financial Officer |
| | | | (principal financial officer) |
| Date: | February 9, 2026 |  |  |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Rod R. Little, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Edgewell Personal Care Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2026

---

| |
|:---|
| /s/ Rod R. Little |
| Rod R. Little |
| Chief Executive Officer |
| *(principal executive officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Francesca Weissman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Edgewell Personal Care Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2026

---

| |
|:---|
| /s/ Francesca Weissman |
| Francesca Weissman |
| Chief Financial Officer |
| *(principal financial officer)* |

---

## Exhibit 32.1

**Exhibit 32.1** 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

The undersigned officer of Edgewell Personal Care Company (the "Company") hereby certifies to his knowledge that the Company's quarterly report on Form 10-Q for the period ended December 31, 2025 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) of 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 9, 2026

---

| |
|:---|
| /s/ Rod R. Little |
| Rod R. Little |
| Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2** 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

The undersigned officer of Edgewell Personal Care Company (the "Company") hereby certifies to his knowledge that the Company's quarterly report on Form 10-Q for the period ended December 31, 2025 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;

Dated: February 9, 2026

---

| |
|:---|
| /s/ Francesca Weissman |
| Francesca Weissman |
| Chief Financial Officer |

---

<br>